Navilyst Medical since Jan 2010
R&D Engineer
Navilyst Medical Jun 2008 - Jan 2010
Packaging Engineer
Boston Scientific May 2007 - May 2008
Co-op
Rochester Institute of Technology Sep 2006 - May 2007
Research Assistant
Education:
Rochester Institute of Technology 2006 - 2007
MS, Packaging Science
B. M. S. College of Engineering 2002 - 2006
BS/BE, Printing Technology
4921 Parkview Pl, Saint Louis, MO 63110 3143623500
Medicine Doctors
Manu Chakravarthy, Saint Louis MO
Work:
Washington University at St. Louis
4921 Parkview Pl, Saint Louis, MO 63110 Umdnj-RWJ-Endocrinology
125 Paterson St, New Brunswick, NJ 08901 Washington University at St. Louis
660 S Euclid Ave, Saint Louis, MO 63110
Us Patents
Use Of An Endogenous Ligand For Peroxisome Proliferator Activated Receptor Alpha To Treat Liver Disorders
Clay F. Semenkovich - Ladue MO, US Manu V. Chakravarthy - Scotch Plains NJ, US John W. Turk - Eureka MO, US
Assignee:
WASHINGTON UNIVERSITY - St. Louis MO
International Classification:
A61K 31/685 C07F 9/06 A61P 1/16 G01N 33/48
US Classification:
514 78, 554 80, 436 63
Abstract:
Compositions comprising the peroxisome proliferator-activated receptor alpha (PPARα)-ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC) are disclosed. These compositions may be used for the prophylaxis and treatment of PPARα-related liver disorders including, but not necessarily limited to, fatty liver disease, to lower lipid and triglyceride levels, and to increase high density lipoprotein levels in animals. Foods modified with 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1GPC) may be used to improve the metabolism of animals.
Compositions And Methods For The Treatment Of Liver Diseases And Disorders
Nadine Daou - Cambridge MA, US Svetlana Marukian - Cambridge MA, US - Cambridge MA, US Svetlana Marukian - Watertown MA, US Michael Hamill - Wellesley MA, US Raffi Afeyan - Cambridge MA, US Sean Carroll - Cambridge MA, US Anthony Tramontin - Brooklyn NY, US Manu Chakravarthy - Newton MA, US
This disclosure provides combinations and methods for improving liver function, e.g., in a subject having a liver disease or disorder, or treating or preventing a liver disease or disorder, e.g., with hyperammonemia or muscle wasting in a subject.
Compositions And Methods For The Treatment Of Liver Diseases And Disorders
- Cambridge MA, US Tony Tramontin - Brooklyn NY, US Manu Chakravarthy - Newton MA, US Raffi Afeyan - Boston MA, US Svetlana Marukian - Watertown MA, US
International Classification:
A61K 31/198 A61K 38/05 A61P 1/16
Abstract:
This disclosure provides compositions and methods for improving liver function, e.g., in a subject having a liver disease or disorder, or treating a liver disease or disorder.
techs efforts in AI and data science to accelerate drug discovery and development. The laboratories will be equipped for advanced research, and over time the center could employ up to 500 people. Manu Chakravarthy, SVP and Global Head of CVRM Product Development, will be the centers site head.